A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome (original) (raw)
Related papers
Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)
Lower urinary tract symptoms, 2018
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT-A). This review summarizes the intravesical therapy for IC/BPS and discusses recent advances in the instillation of liposomal-mediated BoNT-A and other newly developed intravesical therapies.
An update on treatment options for interstitial cystitis
Prz Menopauzalny, 2020
Interstitial cystitis or bladder pain syndrome (IC/BPS) is a chronic pelvic pain syndrome related to the urinary bladder. The ideal treatment should match as much as possible with the pathophysiologic causes of the IC/BPS, but the scarcely available evidence limits this approach, with the majority of available treatments that are primarily targeted to the control of symptoms. The treatment strategies have traditionally focused on the bladder, which is considered the primary end-organ and source of pain. Nevertheless, the growing body of evidence suggests a multifaceted nature of the disease with systemic components. In general, guidelines recommend the personalized and progressive approach, that starts from the more conservative options and then advances toward more invasive and combined treatments. The behavioral changes represent the first and most conservative steps. They can be combined with oral medications or progressively with intravesical instillation of drugs, up to more invasive techniques in a combined way. Despite the multiple available options, the optimal treatment is not easy to be found. Only further investigation on the etiopathogenetic mechanisms, taking into account the differences among subgroups, and the interaction between central and peripherical factors may allow providing a real improvement in the treatment and management of these patients.
2011
Methods: A systematic review of the literature using the MEDLINE database (search dates 1/1/83-7/22/09) was conducted to identify peerreviewed publications relevant to the diagnosis and treatment of IC/BPS. Insufficient evidence was retrieved regarding diagnosis; this portion of the guideline, therefore, is based on Clinical Principles and Expert Opinion. The review yielded an evidence base of 86 treatment articles after application of inclusion/exclusion criteria. These publications were used to create the majority of the treatment portion of the guideline. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinion when insufficient evidence existed. See text and algorithm for definitions and detailed diagnostic, management, and treatment frameworks.
The management of interstitial cystitis: an update
2015
Treating interstitial cystitis (IC) is one of the greatest challenges facing physicians and other health care providers who manage patients with this condition. The symptoms of urinary frequency and urgency, dysuria, and chronic pelvic pain characterize IC, but it is the debilitating pelvic pain associated with IC that is most difficult to control. The pathophysiology of IC pain is poorly understood, but is thought to be a complex entity including nociceptive, visceral, and neuropathic components. There are currently no universally effective therapies available. Oral treatments, however, are frequently used, including nonsteroidal anti-inflammatory drugs, tricyclic antidepressants, gabapentin, and pentosan polysulfate, all of which have shown varying degrees of efficacy. Recognition that IC pain is multifactorial, and probably has a neuropathic component, has led to the use of some of these agents, previously prescribed for other neurologic conditions associated with chronic pain. Intravesical and surgical options are also available, which expands the armamentarium for those who treat pain secondary to IC. Treating IC requires managing all of the symptoms of this disease. This review aims to cover standard and novel treatment options, while concentrating on the management of pain.
Biomedicines, 2021
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic bladder disorder with limited therapeutic options currently available. The present review provides an extensive overview of therapeutic approaches used in in vitro, ex vivo, and in vivo experimental models of IC/BPS. Publications were identified by electronic search of three online databases. Data were extracted for study design, type of treatment, main findings, and outcome, as well as for methodological quality and the reporting of measures to avoid bias. A total of 100 full-text articles were included. The majority of identified articles evaluated therapeutic agents currently recommended to treat IC/BPS by the American Urological Association guidelines (21%) and therapeutic agents currently approved to treat other diseases (11%). More recently published articles assessed therapeutic approaches using stem cells (11%) and plant-derived agents (10%), while novel potential drug targets identified were p...
Treatment of Bladder Pain Syndrome/Interstitial Cystitis 2008: Can We Make Evidence-Based Decisions?
European Urology, 2008
e u r o p e a n u r o l o g y 5 4 ( 2 0 0 8 ) 6 5 -7 8 a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m Abstract Context: Opinions on how to best treat bladder pain/interstitial cystitis are ambiguous. Objective: To review previous and recent literature on this subject to assess the current state of evidence. Evidence acquisition: With important previous papers reviewed for
Interstitial Cystitis/Bladder Pain Syndrome
IntechOpen eBooks, 2023
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a heterogeneous, chronic, and debilitating condition. It affects 400,000 individuals in the United Kingdom. IC/BPS presents with suprapubic pain or discomfort perceived to be related to the urinary bladder with one or more urinary symptoms (e.g., urgency, frequency or nocturia) for more than 6 weeks. The exact etiology is not clearly understood. It can sometimes co-exist with other chronic pain disorders, complicating the diagnosis and management. IC/BPS can adversely impact the quality of life, impede work, and interfere with the sleep, sexual and social life of the affected individual. The contemporary treatments are palliative and aim for symptom control only. There is no cure available presently. Moreover, treatment effects are highly variable; therefore, personalization of treatment is vital for achieving the desired outcomes. Management includes lifestyle modifications, physical therapy, systemic pharmacotherapy, intravesical therapies and surgery. Conservative treatments are usually used first, followed by invasive and combination therapies if required. Treatment should aim beyond symptom improvement and encompass improvement in quality of life. Further research is needed to understand the etiology and pathophysiology of IC/BPS. It will assist in the development of new biomarkers and drug development.
Diagnosis and treatment of interstitial cystitis - literature review
Journal of Education, Health and Sport, 2023
Interstitial cystitis (IC) also known as bladder pain syndrome (BPS) is the presence of chronic or recurrent pain, feelings of tightness or discomfort perceived as associated with the bladder, accompanied by at least one lower urinary tract symptom in the absence of infection or other identifiable causes [1]. These symptoms are pain or burning while urinating; frequent urination; feeling the need to urinate despite having an empty bladder; bloody urine; pressure or cramping in the groin or lower abdomen. There is no laboratory test to make a diagnosis, it is often a diagnosis based on the exclusion of other diseases, one of the diagnostic methods is cystoscopy with the collection of specimens from the bladder and their histopathological examination [2]. Currently there is no causal treatment, only symptomatic treatment is used, such as intravesical administration of hyaluronic acid or surgical methods.